An Economic Model to Value Companion Diagnostics in Non-Small-Cell Lung Cancer
Open Access
- 27 February 2013
- journal article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 10 (2) , 139-147
Abstract
An economic model was used to evaluate the potential economic impact and cost-effectiveness of companion diagnostic testing for patients with non-small-cell lung cancer (NSCLC). A decision analysis model examined alternative patient management strategies for patients with advanced NSCLC who were not amenable to surgical treatment. A review of the literature provided the variables used to develop a timely base case and sensitivity analysis. A potential future scenario was also modeled. The model includes three options: conventional treatment (CT), new treatment (NT) and companion diagnostic (CD) strategy. In the base case analysis based upon current data, the cost per life-year saved for CT, NT option and CD was US$43,367, US$47,394 and US$47,779, respectively. The cost per life-year saved for CT, NT option and CD in a potential future scenario with more expensive, effective targeted therapy was US$47,748, US$69,255 and US$66,369, respectively. In the future scenario, CDs have an incremental cost-effectiveness of US$56,829 per life-year saved when compared with NT as a first-line treatment. This is one demonstration of how CDs may be a cost-effective option for the treatment of patients with advanced NSCLC when the NT is extremely expensive but the outcome is significantly improved.Keywords
Funding Information
- Abbott Molecular of Abbott Laboratories
- MDxHealth and Genomic Health
- Janssen Scientific Affairs, LLC
- Jefferson School of Population Health
This publication has 18 references indexed in Scilit:
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2010
- Progress towards personalized medicineDrug Discovery Today, 2010
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Lung CancerNew England Journal of Medicine, 2008
- Evaluation of Trends in the Cost of Initial Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2008
- The role of companion diagnostics in the development and use of mutation-targeted cancer therapiesNature Biotechnology, 2006
- Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib TrialsJournal of Clinical Oncology, 2005